The Trial That 'Failed' for the Right Reasons
PhagoBurn lost its phages on the shelf — and taught the field that formulation is everything
If the modern phage revival needed a cautionary tale to set against its rescue stories, PhagoBurn provided it. Funded by the European Commission, PhagoBurn was among the first prospective, randomized, controlled, double-blind clinical trials of phage therapy conducted to rigorous Western standards. Its goal was to test whether a cocktail of bacteriophages could treat burn wounds infected with Pseudomonas aeruginosa, a pathogen that is both a leading cause of deadly burn-wound sepsis and increasingly resistant to antibiotics. Expectations ran high: success here could have helped legitimize phage therapy for regulators worldwide.
The design was sound on paper. Between July 2015 and January 2017, investigators across nine burn centres in France and Belgium recruited 27 adult patients with P. aeruginosa-infected burns and randomized them to one of two daily topical treatments for seven days: the phage cocktail, called PP1131 — a blend of 12 natural lytic anti-Pseudomonas phages — or standard of care, a 1% sulfadiazine silver emulsion cream. The intended phage dose was 1 × 10⁶ plaque-forming units (PFU) per millilitre. The trial measured how quickly each treatment reduced the bacterial burden in the wound.
The headline outcome looked like a defeat. Published in The Lancet Infectious Diseases in 2019 by Jault, Leclerc, and colleagues, the trial found that the phage cocktail reduced bacterial burden more slowly than standard care. The median time to a sustained reduction was 144 hours in the phage group versus 47 hours with the silver-sulfadiazine cream — a statistically significant disadvantage (hazard ratio 0.29). The trial was stopped early. A naive reading was that phages simply didn't work.
But the real story was in the vials. Investigators discovered that the PP1131 cocktail had lost potency during manufacturing and storage. The titre of viable phages had collapsed, and patients ultimately received a preparation roughly 1 × 10² PFU/mL — about ten thousand times weaker than the intended 1 × 10⁶ PFU/mL. The trial had not really tested phage therapy at a therapeutic dose. It had tested a drastically under-dosed product. As the authors put it, at very low concentrations the cocktail decreased bacterial burden more slowly than standard of care — a conclusion about that diluted batch, not about the underlying biology of phages.
The culprit was formulation and stability, not the concept. Combining 12 different phages into one stable liquid cocktail proved deceptively hard: different phages can degrade at different rates, interfere with one another, and lose infectivity over the weeks between production and a patient's bedside. The crucial vulnerability is that phages are living biological entities whose active ingredient — infectious virions — can quietly decay in storage in a way a small-molecule drug does not.
The lesson PhagoBurn taught became one of the field's most cited. It established that manufacturing, quality control, titre verification, and stability testing are not afterthoughts but central to any phage trial; that the delivered dose must be confirmed at the point of administration, not merely at production; and that future studies should use higher, verified phage concentrations and employ phagograms — susceptibility tests matching a patient's bacteria to active phages — in larger cohorts. The authors themselves recommended exactly this path forward.
Far from discrediting phage therapy, PhagoBurn sharpened it. It forced the field to professionalize its pharmaceutical side and to treat phages with the same chemistry-manufacturing-and-controls rigor demanded of any biologic. A trial that 'failed' on its primary endpoint succeeded as a teacher — a reminder that even the most elegant biological weapon is only as good as the dose that actually reaches the wound.